Document is current
Any future updates will be listed below
-
Authors
Lim, Soo https://orcid.org/0000-0002-4137-1671
Bae, Jae Hyun https://orcid.org/0000-0002-1384-6123
Kwon, Hyuk-Sang https://orcid.org/0000-0003-4026-4572
Nauck, Michael A. https://orcid.org/0000-0002-5749-6954
- License Information
-
More Information
Article History
Accepted: 14 October 2020
First Online: 13 November 2020
Competing interests
: S.L. has been a member of advisory boards or has consulted with Merck, Sharp & Dohme and NovoNordisk. S.L. has received grant support from AstraZeneca, Merck, Sharp & Dohme and Astellas. S.L. has also served on the speakers’ bureau of AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Merck, Sharp & Dohme, CKD Pharmaceutical and NovoNordisk. H.-S.K. has been a member of advisory boards or has consulted with Pfizer, Boehringer Ingelheim, Novartis, Daewoong Pharmaceutical, JW Pharmaceutical and NovoNordisk. H.-S.K. has received grant support from AstraZeneca. H.-S.K. has also served on the speakers’ bureau of Eli Lilly & Co., Merck, Sharp & Dohme, YUHAN, Dong-A Pharmaceutical and NovoNordisk. M.A.N. has been a member of advisory boards or has consulted with AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Fractyl, GlaxoSmithKline, Menarini/Berlin-Chemie, Merck, Sharp & Dohme and NovoNordisk. M.A.N. has received grant support from AstraZeneca, Eli Lilly & Co., Menarini/Berlin-Chemie, Merck, Sharp & Dohme, Novartis Pharma and NovoNordisk. M.A.N. has also served on the speakers’ bureau of AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Menarini/Berlin-Chemie, Merck, Sharp & Dohme, NovoNordisk and Sun Pharma. J.H.B. declares no competing interests.
Free to read: This content has been made available to all.
